Longevity, Immune & Hormonal Peptides: Research Overview

TL;DR: This pillar covers four distinct research clusters, mitochondria-derived peptides (MOTS-c, Humanin), telomere-biology peptides (Epithalon), thymic/immune peptides (Thymosin Alpha-1, Thymalin), and melanocortin/HPG-axis peptides (Bremelanotide/PT-141, Kisspeptin). Evidence tiers range from a single FDA-approved compound (bremelanotide, narrow indication) to preclinical-only work. All others in this cluster are research compounds without general FDA approval for human use, and all are classified by WADA as prohibited non-approved or category-specific substances.

Research-Use Disclaimer: This article is for educational and research reference purposes only. The compounds discussed are research chemicals not approved by the FDA for general human use (see per-compound regulatory notes). This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published peer-reviewed research. For adults 21+ with a research interest only.

Why Group These Compounds into One Pillar?

Each sub-area’s evidence tier is rated differently and researchers should not generalize across them. The sections below address each cluster’s mechanistic framework, evidence landscape, and regulatory status independently.

Cluster 1: Mitochondria-Derived Peptides, MOTS-c and Humanin

Mitochondria-derived peptides (MDPs) are a class of small signaling peptides encoded by short open reading frames (sORFs) within the mitochondrial genome, a genomic region long assumed to encode only ribosomal components and transfer RNAs. The discovery that the mitochondrial 12S rRNA region harbors functional peptide-encoding sequences has opened a new area of cellular signaling research.

What Is MOTS-c and What Mechanism Does the Research Document?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA region, first characterized in 2015. Its primary documented action involves translocating from mitochondria to the nucleus under conditions of metabolic stress, where it modulates nuclear gene expression.

The foundational study by Lee et al. (2015), published in Cell Metabolism, reported that MOTS-c’s cellular mechanism involves inhibition of the folate cycle and its linked de novo purine biosynthesis, leading to AMPK activation in skeletal muscle, and that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity (PMID: 25738459). This mouse model data established MOTS-c’s primary metabolic research interest.

A follow-up study by Kim et al. (2018), also in Cell Metabolism, provided mechanistic depth, demonstrating that MOTS-c translocates to the nucleus under metabolic stress in an AMPK-dependent manner and regulates a broad range of nuclear genes in response to glucose restriction, including those containing antioxidant response elements (ARE), interacting with stress-responsive transcription factors such as NRF2 (PMID: 29983246). This mitonuclear communication model is a central element of current MOTS-c research framing.

A 2023 review by Zheng et al. in Frontiers in Endocrinology surveyed MOTS-c’s broader therapeutic research landscape, noting that MOTS-c plasma levels decrease with age and that preclinical models have investigated its potential in aging, cardiovascular disease, insulin resistance, and inflammation, while noting that no effective clinical application method has been established (PMID: 36761202). MOTS-c has no FDA approval. Read the compound profile: What Is MOTS-c?

What Is Humanin and What Does the Research Document?

Humanin is a 21-amino acid mitochondria-derived peptide, also encoded within the 12S rRNA region, and the first MDP characterized in the literature. Research describes it as cytoprotective and neuroprotective across multiple model systems, with documented declining levels in aging and in certain neurodegenerative disease states.

A landmark multi-species study by Yen et al. (2020) in the journal Aging reported that overexpression of humanin in C. elegans increased lifespan in a daf-16-dependent manner; humanin transgenic mice showed phenotypic overlap; exogenous humanin treatment in middle-aged mice improved metabolic healthspan parameters and reduced inflammatory markers; and humanin levels were found to be elevated in children of centenarians compared with age-matched controls (PMID: 32575074). These cross-species correlational findings represent some of the most compelling data linking MDPs to longevity phenotypes, though causal human evidence is not yet established.

In neurological research contexts, a 2023 study by Kim in Theranostics examined intranasal delivery of humanin in Parkinson’s disease mouse models, finding that HN peptide administered intranasally reached the brain primarily via trigeminal pathways, induced PI3K/AKT signaling, enhanced mitochondrial biogenesis, and resulted in neuroprotection and behavioral recovery in the animal model (PMID: 37351170). This is preclinical data; no human RCTs for Humanin in neurological conditions have been published as of 2026.

Cluster 2: Telomere-Biology Peptides, Epithalon

Epithalon (also spelled Epitalon; chemical name: Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from epithalamin, a natural polypeptide extracted from the pineal gland. It is studied in the context of telomere biology and aging, with the primary research focus on its documented ability to influence telomerase enzyme activity and telomere length in cell and animal models.

What Does the Epithalon Research Document?

Epithalon is one of the more extensively studied research peptides in the longevity category, largely through the work of Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. A 2005 analysis by Khavinson et al. in Neuro Endocrinology Letters proposed a molecular mechanism by which regulatory peptides interact with DNA, identifying a complementary binding sequence ATTTTC, and its reverse complement, found repeatedly in the telomerase promoter region that is computationally predicted to be targeted by epitalon (PMID: 15990728). This computational/biophysical analysis provided early mechanistic framing for subsequent telomerase-focused experiments.

A more recent study by Al-Dulaimi et al. (2025), published in Biogerontology, characterized Epithalon’s effects in human cell lines, reporting that Epithalon induced dose-dependent telomere length extension in normal epithelial and fibroblast cells through upregulation of hTERT mRNA expression and telomerase enzyme activity; in cancer cell lines, significant telomere length extension also occurred through ALT (Alternative Lengthening of Telomeres) activation, with only minor ALT activity in normal cells, suggesting cancer-cell specificity of the ALT mechanism (PMID: 40908429). This represents the most current and methodologically detailed cell-culture evidence for Epithalon’s telomere effects.

Evidence tier and honest assessment: Epithalon’s research base spans computational modeling, animal aging studies, and the cell-culture data above. Published large human RCTs are not available in the indexed peer-reviewed literature as of 2026. Epithalon is not FDA approved for any human use and is listed by WADA under Section S0 (Non-Approved Substances).

Cluster 3: Thymic and Immune Peptides, Thymosin Alpha-1 and Thymalin

Thymic peptides are a class of compounds originally isolated from or modeled on thymic tissue, studied for their role in T-cell differentiation and immune modulation. Of all compounds in this pillar cluster, Thymosin Alpha-1 carries the most extensive published clinical evidence base, more than 30 clinical trials and over 11, 000 subjects across published literature, making it the highest-evidence compound discussed in this article.

What Is Thymosin Alpha-1 and What Does the Clinical Evidence Show?

Thymosin Alpha-1 (Tα1; brand name Zadaxin; also referred to as thymalfasin) is a 28-amino acid synthetic polypeptide originally isolated from thymic tissue. It is characterized in the literature as a pleiotropic immune modulator that acts through Toll-like receptors in both myeloid and plasmacytoid dendritic cells, leading to activation of immune signaling pathways and cytokine production.

A foundational clinical review by Ancell et al. (2001) in the American Journal of Health-System Pharmacy summarized early-phase trial data, including a randomized controlled trial in hepatitis B patients in which HBV DNA clearance at six months was documented in 40.6% and 25.6% of patients treated with Tα1 for 6 and 12 months, respectively, compared with 9.4% of untreated controls; combination Tα1 and IFN-alpha 2b for hepatitis C showed ALT normalization in 71% versus 35% for IFN-alpha 2b alone in one trial (PMID: 11381492). These hepatitis trials represent Tier 1 evidence (human RCTs) for Tα1, within a specific infectious disease context.

A 2016 review by King and Tuthill in Vitamins and Hormones placed these findings in broader mechanistic context, characterizing Tα1 as a compound that acts through TLR signaling in dendritic cells to activate immune cell subsets and stimulate cytokine production, with preclinical and clinical studies demonstrating improvements in immune system cell subsets across infection, cancer, and immune-suppression contexts (PMID: 27450734).

A 2025 review by Simonova et al. in the International Journal of Molecular Sciences extended this to aging-specific contexts, noting that Tα1 stimulates T-cell differentiation, enhances thymic output, and modulates dendritic cell and macrophage activity; preclinical and clinical studies show that Tα1 can improve vaccine response in elderly subjects and mitigate immunosenescence, the age-related decline in immune function linked to thymic involution (PMID: 41373628).

A comprehensive 2024 safety and efficacy review by Dinetz and Lee covering more than 11, 000 subjects in over 30 trials concluded that Tα1 consistently demonstrated safety and efficacy across COVID-19, autoimmune disorders, and cancer, though the FDA restricted it from compounding pharmacies in 2023 alongside 21 other peptides (PMID: 38308608). Read the compound profile: What Is Thymosin Alpha-1?

What Is the Sepsis Evidence Context for Thymosin Alpha-1?

Beyond its hepatitis and aging research contexts, Tα1 has been studied in sepsis, one of its most clinically relevant investigated applications. A 2018 review by Pei et al. in Expert Opinion on Biological Therapy summarized clinical studies in sepsis and septic shock, finding that single or combined treatment with Tα1 reduced mortality rate in sepsis, improved HLA-DR expression on monocytes, and diminished secondary infection incidence, but noted that sepsis’s clinical heterogeneity makes generalization difficult and that future trials should focus on immunosuppressive subpopulations (PMID: 30063866). This is an important evidence nuance: consistent directional findings across trials, but without the homogeneous population needed for definitive efficacy claims.

Cluster 4: Melanocortin and HPG-Axis Peptides, Bremelanotide and Kisspeptin

The final cluster groups two peptides that operate through distinct but thematically linked neuroendocrine pathways: bremelanotide (PT-141) acts on melanocortin receptors in the central nervous system, while kisspeptin acts as the upstream hypothalamic trigger for the entire hypothalamic-pituitary-gonadal (HPG) axis. Both are studied for their roles in neuroendocrine signaling rather than for direct anabolic or tissue-level effects.

What Is Bremelanotide (PT-141) and What Receptor Does It Target?

Bremelanotide is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), developed by Palatin Technologies. Its primary pharmacological mechanism is agonism at melanocortin receptors MC3R and MC4R, centrally expressed receptors involved in neuroendocrine and autonomic signaling. Unlike peripherally acting vasodilators, bremelanotide’s documented mechanism is central: it acts on brain pathways rather than on peripheral vascular tissue.

A first-approval regulatory summary by Dhillon and Keam (2019) in Drugs documented that bremelanotide received FDA approval in 2019 (brand name Vyleesi) as an on-demand subcutaneous prescription therapy for a specific and narrow indication, acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, based on Phase 3 trial evidence, with its mechanism described as high-affinity agonism at the MC4 receptor thought to be important for neuroendocrine signaling relevant to the approved indication (PMID: 31429064). This is the only FDA approval in this compound’s history and does not extend to other populations or indications.

An earlier Phase 2 double-blind randomized trial by Diamond et al. (2006), published in the Journal of Sexual Medicine, examined a single intranasal dose in 18 premenopausal women with female sexual arousal disorder, finding that more women reported moderate or high desire following bremelanotide versus placebo (P = 0.0114), with a trend toward positive genital arousal responses; vaginal vasocongestion on photoplethysmography did not change significantly, suggesting a central rather than peripheral mechanism of action (PMID: 16839319). This mechanistic dissociation between central and peripheral response has been cited in subsequent mechanistic framing of MC4R agonism.

Bremelanotide research has also extended beyond the approved indication. A 2024 cell-culture study by Suzuki et al. in Anticancer Research examined bremelanotide in human glioblastoma cell lines, reporting that bremelanotide reduced survivin expression and induced cell death in glioblastoma cells at concentrations non-toxic to normal cells, with effects canceled by MC3R/MC4R antagonism, identifying these melanocortin receptors as potential targets in glioblastoma (PMID: 39197897). This is early-stage, in vitro data and does not constitute clinical evidence. WADA prohibits bremelanotide under Section S0 for athletes subject to anti-doping rules. Read the compound profile: What Is PT-141?

What Is Kisspeptin and Why Is It Researched in the HPG-Axis Context?

Kisspeptin is an endogenous neuropeptide encoded by the KISS1 gene, acting via its receptor KISS1R to stimulate GnRH (gonadotropin-releasing hormone) secretion from hypothalamic neurons, making it the upstream trigger of the entire hypothalamic-pituitary-gonadal axis. Research interest in kisspeptin derives from its central role as the “GnRH pulse generator” in normal reproductive endocrinology.

A comprehensive 2022 review by Xie et al. in Frontiers in Endocrinology characterized kisspeptin’s role across the HPG axis, noting that kisspeptin neurons in the arcuate nucleus co-express neurokinin B and dynorphin (forming KNDy neurons) that participate in both positive and negative estrogen feedback on GnRH secretion; mutations in KISS1 or KISS1R have been associated with clinical presentations including idiopathic hypogonadotropic hypogonadism (iHH) and central precocious puberty (CPP) (PMID: 35837314). This genetic and clinical phenotype evidence establishes kisspeptin as a causal regulator of the HPG axis in humans, not merely correlational.

A 2021 review by Spaziani et al. in Molecular and Cellular Endocrinology provided mechanistic framing of the puberty activation cascade, describing kisspeptin’s role as initiating the “kiss” between kisspeptin and hypothalamic GnRH neurons, the onset of pulsatile GnRH production that drives pubertal development, and contextualizing this within a complex network of neuroendocrine regulators and genetic mediators (PMID: 33271219). This foundational biology framing is essential context for researchers investigating kisspeptin peptide analogues. Read the compound profile: What Is Kisspeptin?

Evidence-Tier Summary Across This Cluster

The compounds in this pillar span a wide range of evidence levels. The table below reflects the state of the peer-reviewed literature as of mid-2026.

The honest framing researchers should apply: Even the highest-evidence compound in this cluster (bremelanotide) holds a narrow approval for a single specific indication, not a general endorsement of the melanocortin system for any other purpose. The remaining compounds span a spectrum from robust but non-US-approved clinical evidence (Thymosin Alpha-1) to early-stage cell-culture data (Epithalon) and animal-only models (MOTS-c). Preclinical findings across multiple species are hypothesis-generating, not clinically conclusive. For full evidence-tier methodology, see: How to Read an Evidence Tier.

Regulatory Status: WADA and FDA

WADA Status for This Cluster

All compounds covered in this pillar are prohibited by the World Anti-Doping Agency. Bremelanotide, Thymosin Alpha-1, MOTS-c, Humanin, Epithalon, and Kisspeptin all appear on the WADA Prohibited List under Section S0: Non-Approved Substances, which covers any pharmacological substance with no current approval by a recognized regulatory authority for human therapeutic use. The fact that bremelanotide holds a narrow FDA approval does not exempt it from S0 categorization because WADA applies S0 to any use outside the specific approved indication, and WADA does not recognize narrow approvals as general therapeutic endorsements. The S0 prohibition applies both in-competition and out-of-competition for all athletes subject to WADA rules.

FDA Status Overview

Within the United States: bremelanotide (Vyleesi) is FDA approved for one specific indication. Thymosin Alpha-1 has been restricted from compounding pharmacies as of 2023. MOTS-c, Humanin, Epithalon, and Kisspeptin (synthetic peptide analogues) have no FDA approval for any human therapeutic use. Researchers should consult current FDA guidance directly, as the regulatory landscape for peptide compounds can change and this article reflects publicly available information as of publication date.

Frequently Asked Questions

What are mitochondria-derived peptides and why are researchers studying them?

Mitochondria-derived peptides (MDPs) are small peptides encoded by short open reading frames within the mitochondrial genome, a region previously believed to encode only ribosomal and transfer RNA components. MOTS-c and Humanin are the two most studied MDPs. Research has documented that MOTS-c translocates to the nucleus under metabolic stress to regulate gene expression through AMPK and NRF2 pathways, while Humanin shows neuroprotective and cytoprotective properties across multiple animal and cell-culture systems. Both represent preclinical-stage research compounds with no current FDA approval.

What does the research say about Epithalon and telomere length?

Epithalon is a synthetic tetrapeptide studied for its effects on telomere biology. A 2025 study in Biogerontology documented dose-dependent telomere length extension in normal human cell lines through hTERT mRNA upregulation and telomerase enzyme activation, with ALT activation specific to cancer cell lines. Earlier computational analyses proposed a specific DNA binding sequence in the telomerase promoter region. This is cell-culture and computational data; no large human RCTs for Epithalon’s telomere effects have been published as of 2026.

Is Thymosin Alpha-1 FDA approved?

In the United States, Thymosin Alpha-1 is not currently FDA approved as a prescription drug and was restricted from US compounding pharmacies in 2023. It is approved in other countries (including China) for specific hepatitis and immune indications. More than 30 clinical trials covering over 11, 000 subjects have been published, making it among the more clinically studied compounds in this category. None of this changes its US regulatory status.

What is bremelanotide (PT-141) and what receptor does it act on?

Bremelanotide (Vyleesi) is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone. It acts as an agonist at melanocortin receptors MC3R and MC4R, which are expressed in the brain and are involved in neuroendocrine signaling. The FDA approved bremelanotide in 2019 for a narrow specific indication in premenopausal women only. WADA prohibits it under Section S0 for all athletes subject to anti-doping rules. The research literature also documents MC3R/MC4R as pharmacological targets in other research contexts.

Research use only. Not intended for human use. Not FDA approved (except bremelanotide/Vyleesi for its specific narrow indication). This article documents published scientific literature for educational and reference purposes only and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources via PubMed, read them in full. Must be 21+.